KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that Laurence Reid, Ph.D., has been appointed to the Company’s ...

The U.S. Food and Drug Administration has approved BridgeBio's drug for a rare and deadly heart condition, the company said ...

A broad licensing and research alliance will hand Sarepta four clinical-stage candidates, while Arrowhead receives $500 ...

Analyst Patrick Trucchio of H.C. Wainwright reiterated a Buy rating on Alnylam Pharma (ALNY – Research Report), boosting the price target to ...

Algert Global LLC increased its holdings in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Free Report) by 401.3% ...

Canaccord Genuity analyst Whitney Ijem maintained a Buy rating on Alnylam Pharma (ALNY – Research Report) yesterday and set a price target of ...

PNC Financial Services Group Inc. boosted its stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Free Report) by 1.2% in ...

Delving into the details, we found 5% of traders were bullish, while 84% showed bearish tendencies. Out of all the trades we spotted, 14 were puts, with a value of $931,387, and 5 were calls, valued ...

CAMBRIDGE, MA—Kevin Joseph Fitzgerald, the Chief Scientific Officer and Executive Vice President, Head of Research at Alnylam Pharmaceuticals , Inc. (NASDAQ:ALNY), recently sold a significant portion ...

On Tuesday, Canaccord Genuity maintained a Buy rating on shares of Alnylam Pharmaceuticals (NASDAQ:ALNY), with a price target of $384.00. The firm's analyst commented on recent developments in the ...

Financial giants have made a conspicuous bearish move on Alnylam Pharmaceuticals. Our analysis of options history for Alnylam Pharmaceuticals ALNY revealed 19 unusual trades. Delving into the ...

On Monday, BMO Capital maintained its optimistic outlook on shares of Alnylam Pharmaceuticals (NASDAQ:ALNY), reiterating an Outperform rating with a $300.00 price target. The firm's confidence is ...